| Market Cap | 50.97B | P/E | 21.28 | EPS this Y | 21.10% | Ern Qtrly Grth | 34.50% |
| Income | 355.04B | Forward P/E | 21.75 | EPS next Y | 5.20% | 50D Avg Chg | 4.00% |
| Sales | 1.08T | PEG | 633.18 | EPS past 5Y | 18.89% | 200D Avg Chg | 13.00% |
| Dividend | 272.00% | Price/Book | 0.03 | EPS next 5Y | 7.05% | 52W High Chg | -3.00% |
| Recommedations | - | Quick Ratio | 4.02 | Shares Outstanding | 1.65B | 52W Low Chg | 28.00% |
| Insider Own | 59.91% | ROA | 15.63% | Shares Float | 639.46M | Beta | 0.54 |
| Inst Own | 18.49% | ROE | 21.75% | Shares Shorted/Prior | -/- | Price | 29.36 |
| Gross Margin | 69.46% | Profit Margin | 32.74% | Avg. Volume | 327 | Target Price | - |
| Oper. Margin | 50.12% | Earnings Date | Oct 25 | Volume | 705 | Change | 0.00% |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.